PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.

PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.

Item
http://www.wikidata.org/entity/Q40218014
Caffeic Acid phenethyl ester is a potential therapeutic agent for oral cancerFrequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkersOncogenic mutations of PIK3CA in human cancersThe determinants of head and neck cancer: Unmasking the PI3K pathway mutationsFGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.PIK3CA mutations in mucinous cystic neoplasms of the pancreas.mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma.Whole transcriptome sequencing identifies tumor-specific mutations in human oral squamous cell carcinoma.Mammalian target of rapamycin and head and neck squamous cell carcinomaCommon oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian originPIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancerInterleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer.PTEN deficiency contributes to the development and progression of head and neck cancer.Aberrant kinase signaling: lessons from head and neck cancer.Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibitionDissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance.PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine.Quercetin suppresses cellular migration and invasion in human head and neck squamous cell carcinoma (HNSCC)Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approachesDysregulated molecular networks in head and neck carcinogenesisMutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas.Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma.Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.Chromosomal instability, aneuploidy and routine high-resolution DNA content analysis in oral cancer risk evaluation.The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Human papillomavirus-associated adenocarcinoma of the base of tongue: potentially actionable genetic changes.Defining the genomic landscape of head and neck cancers through next-generation sequencing.TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).Genomic sequencing and precision medicine in head and neck cancers.Investigational drugs for head and neck cancer.PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
P2860
Q26822487-FA73D4D2-93C7-4991-ABAF-6EE472E02BBEQ27852227-0F17D99E-A8D2-4E22-AE69-49F02111AF2AQ28284802-45BE56BD-D9E2-4C92-BB02-E6B3592AF88DQ30365726-ABC861D6-1E90-455F-9AB8-EC02AFD5504BQ33745140-7A8990A0-E37D-4AA2-9A4B-9A5AEEA179DCQ33942405-8E6DB707-1558-4B4B-80E8-DECB2CCD1370Q34049613-3BD8C598-B2AA-4DA6-A5E7-1510AE57AAF5Q34330763-39DE0C73-9C0F-4593-9F80-45F9ED460B2EQ34978926-F2E4272B-3BE3-4699-BE64-BDC677114150Q35027222-4825AB11-693E-473F-AD11-40BA960F58A9Q35041632-7706AF18-0E6F-4572-8117-99E49945C74CQ35068192-D3DF28DA-6C16-4601-9F17-A508454143B9Q35994228-17A6A663-D33D-4348-9C05-01C12081AE99Q36237554-34C9D5AC-4500-48A6-AFD4-539AD87EFD64Q36629444-BC3F0FAC-F318-4928-B2AB-01EAABC0936CQ36801074-39E12128-1FD8-4D79-AEE4-2C23D7CE0ACFQ36839797-65807EC2-DD6A-4F23-B644-C8099619AB8BQ36868012-83A66770-A2B0-4371-BE90-38CC175A6BAFQ37008823-744BD3D1-D764-4D61-91D4-957E7B686B8FQ37025086-4D24DF09-FD82-4628-85AD-780CADF98255Q37164556-D9BE562B-6AC1-4161-AC12-C2DE4C87DF4EQ37165861-34EBA971-D65A-413A-A3C4-B5D0BB660163Q37176596-7AEECCF4-FD28-409D-8E31-7D1C6D98E1C6Q37192606-570C1EF0-FB33-4987-86C4-D57E769DE290Q37274623-3F88FD6F-B17A-450C-9B2A-63E7E6160AC1Q37371256-798181FC-68A2-4378-80EA-AB9DB1569F22Q37474182-90682F1E-2F3B-4878-A1FB-820F876DD394Q37627634-8D2DA73F-E417-4961-90F3-13F991D4C2A8Q37670693-9E10BE47-A01F-4D8E-B325-B17310AAEAA4Q37690668-C162B6E2-4FB0-45EF-BFCE-09D00AFB8D46Q37728444-C6588E8C-7182-4FF0-966A-151EC7597C4BQ38058129-F66658AC-00F2-46EC-A4D3-4E96A58FB463Q38161944-08AAF9E9-8483-4D7A-B741-E172F3488ED3Q38164587-93764A9F-5648-4439-98BC-61DCDB25AF18Q38203938-B3A13656-D673-4BA1-B85E-F398AEEE2B76Q38388694-61F9EB30-BFF2-4C94-8957-DC3B2C76F188Q38776454-E4FBCD1D-B835-4493-B2BA-4DC31B25DAD5Q38800788-949DF7BA-DDEF-4789-89BF-5F7C45B75BBCQ39050475-6294B1B2-3382-45FA-91F8-AA7375239891Q39532332-C4774BFD-A09A-4964-B9CD-0F375D58AB9D
P2860

PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.

Item
http://www.wikidata.org/entity/Q40218014
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
PIK3CA mutation is an oncogeni ...... oral squamous cell carcinoma.
@en
type
label
PIK3CA mutation is an oncogeni ...... oral squamous cell carcinoma.
@en
prefLabel
PIK3CA mutation is an oncogeni ...... oral squamous cell carcinoma.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P4510
P478
P577
P5875
P698
P921
P356
P1433
P1476
PIK3CA mutation is an oncogeni ...... oral squamous cell carcinoma.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1349-7006.2006.00343.X
P433
P4510
P478
P577
P5875
P698
P921